Matinas BioPharma Holdings
Market Cap
US$152.0m
Last Updated
2020/07/03 00:14 UTC
Data Sources
Company Financials +
Executive Summary
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has Matinas BioPharma Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MTNB's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.9%
MTNB
1.6%
US Biotechs
1.6%
US Market
1 Year Return
-11.5%
MTNB
22.8%
US Biotechs
4.8%
US Market
Return vs Industry: MTNB underperformed the US Biotechs industry which returned 22% over the past year.
Return vs Market: MTNB underperformed the US Market which returned 4.3% over the past year.
Shareholder returns
| MTNB | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.9% | 1.6% | 1.6% |
| 30 Day | -10.4% | 5.6% | 2.3% |
| 90 Day | 43.5% | 31.2% | 29.5% |
| 1 Year | -11.5%-11.5% | 24.0%22.8% | 7.1%4.8% |
| 3 Year | -51.9%-51.9% | 33.4%29.0% | 37.1%28.1% |
| 5 Year | -23.0%-23.0% | 0.8%-5.0% | 67.2%48.6% |
Price Volatility Vs. Market
How volatile is Matinas BioPharma Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
How Much Of Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Do Insiders Own?Valuation
Is Matinas BioPharma Holdings undervalued compared to its fair value and its price relative to the market?
2.06x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MTNB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MTNB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MTNB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MTNB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTNB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MTNB is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Matinas BioPharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
49.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MTNB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MTNB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MTNB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MTNB's revenue (89.1% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: MTNB's revenue (89.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MTNB's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Matinas BioPharma Holdings performed over the past 5 years?
-9.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTNB is currently unprofitable.
Growing Profit Margin: MTNB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MTNB is unprofitable, and losses have increased over the past 5 years at a rate of -9.4% per year.
Accelerating Growth: Unable to compare MTNB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: MTNB has a negative Return on Equity (-23.67%), as it is currently unprofitable.
Next Steps
Financial Health
How is Matinas BioPharma Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: MTNB's short term assets ($74.0M) exceed its short term liabilities ($2.5M).
Long Term Liabilities: MTNB's short term assets ($74.0M) exceed its long term liabilities ($4.0M).
Debt to Equity History and Analysis
Debt Level: MTNB is debt free.
Reducing Debt: MTNB currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTNB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MTNB has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 13% each year.
Next Steps
Dividend
What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MTNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MTNB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTNB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTNB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MTNB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Jerry Jabbour (46yo)
2.33yrs
Tenure
US$1,325,176
Compensation
Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. M ...
CEO Compensation Analysis
Compensation vs Market: Jerry's total compensation ($USD1.33M) is about average for companies of similar size in the US market ($USD1.34M).
Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.33yrs | US$1.33m | 0.41% $618.8k | |
| Chief Financial Officer | 1.5yrs | US$774.05k | 0.048% $72.7k | |
| Chief Development Officer | 1.75yrs | US$698.14k | no data | |
| Chief Medical Officer | 1.42yrs | US$781.38k | no data | |
| Chief Scientific Officer | 4.83yrs | US$294.64k | 0.72% $1.1m | |
| Executive Director and Head of Manufacturing & Supply Chain | 1.75yrs | no data | no data |
1.8yrs
Average Tenure
53yo
Average Age
Experienced Management: MTNB's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.33yrs | US$1.33m | 0.41% $618.8k | |
| Independent Vice Chairman of the Board | 1.83yrs | US$160.00k | 0.20% $307.9k | |
| Independent Chairman of the Board | 7yrs | US$176.00k | 2.26% $3.4m | |
| Director | 7yrs | US$130.00k | 2.95% $4.5m | |
| Independent Director | 6.67yrs | US$155.00k | 0.31% $478.1k | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.58yrs | no data | no data | |
| Independent Director | 3.25yrs | US$151.50k | 0.058% $88.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.1yrs
Average Tenure
55.5yo
Average Age
Experienced Board: MTNB's board of directors are considered experienced (4.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MTNB insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.1%.
Top Shareholders
Company Information
Matinas BioPharma Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Matinas BioPharma Holdings, Inc.
- Ticker: MTNB
- Exchange: AMEX
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$152.006m
- Shares outstanding: 197.49m
- Website: https://www.matinasbiopharma.com
Number of Employees
Location
- Matinas BioPharma Holdings, Inc.
- 1545 Route 206 South
- Suite 302
- Bedminster
- New Jersey
- 7921
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MTNB | AMEX (NYSE MKT LLC) | Yes | Common Stock | US | USD | Jun 2014 |
| 6LJ | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2014 |
Biography
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/03 00:14 |
| End of Day Share Price | 2020/07/02 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.